Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - BTIG raised its price target on Guardant Health (NASDAQ:GH) to $80.00 from $70.00 on Thursday, while maintaining a Buy rating following the company’s Analyst Day. The stock, currently trading at $57.67, has already delivered impressive returns with a 158.61% gain over the past year. According to InvestingPro data, analyst targets currently range from $47 to $72.
The research firm noted that Guardant Health exceeded expectations by raising its average selling price assumptions and increasing its 2028 revenue target by $200 million.
BTIG highlighted that Guardant Health has accelerated its break-even target by one year to year-end 2027, which represents a significant improvement in the company’s financial outlook.
The firm also pointed to several new material updates announced during the Analyst Day that BTIG believes "are not well-understood" by the market, suggesting potential upside for investors.
Guardant Health remains one of BTIG’s "Top Picks for 2025," with the firm citing "important catalysts that will propel this growth engine to hum for years."
In other recent news, Guardant Health has seen several positive analyst actions concerning its stock ratings and price targets. Stifel raised its price target for Guardant Health to $70, citing the company’s efforts in data creation and portfolio improvements, along with upcoming product launches. UBS reiterated its Buy rating on Guardant Health, aligning with its updated "Emerging Growth Dx Handbook," which analyzes market trends in specialty diagnostics. Canaccord Genuity maintained its Buy rating and a $65 price target, anticipating that the company’s Investor Day would highlight recent progress. Similarly, BTIG held its Buy rating and $70 price target, viewing the Analyst Day as an opportunity for Guardant Health to discuss its technological advancements. Wells Fargo resumed coverage with an Overweight rating and set a price target of $72, focusing on the company’s oncology strategy and diverse portfolio. These developments reflect a strong consensus among analysts about Guardant Health’s potential growth and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.